Literature DB >> 23241738

Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

F Ostronoff1, F Milano, T Gooley, J A Gutman, P McSweeney, F B Petersen, B M Sandmaier, R Storb, C Delaney.   

Abstract

Reduced-intensity conditioning (RIC) regimens in cord blood transplant (CBT) are increasingly utilized for older patients and those with comorbidities. However, the optimal conditioning regimen has not yet been established and remains a significant challenge of this therapeutic approach. Antithymocyte globulin (ATG) has been incorporated into conditioning regimens in order to decrease the risk of graft failure; however, use of ATG is often associated with infusion reactions and risk of post-transplant complications. We report the results of a non-ATG-containing RIC regimen, where patients received 2 Gy TBI unless they were considered to be at higher risk of graft failure, in which case they received 3 Gy of TBI. Thirty patients underwent CBT using this protocol for high-risk hematological malignancies. There was only one case of secondary and no cases of primary graft failure. At 1 year, estimates of non-relapse mortality, OS and PFS were 29%, 53% and 45%, respectively. The cumulative incidences of grade III-IV acute and chronic GVHD were 14% and 18%, respectively. In summary, the results of this study demonstrate that this non-ATG-containing conditioning regimen provides a low incidence of graft failure without increasing regimen-related toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241738      PMCID: PMC3680599          DOI: 10.1038/bmt.2012.243

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

1.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

2.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

3.  High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.

Authors:  H Narimatsu; M Watanabe; A Kohno; K Sugimoto; Y Kuwatsuka; T Uchida; M Murata; K Miyamura; Y Morishita
Journal:  Bone Marrow Transplant       Date:  2008-01-14       Impact factor: 5.483

4.  Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

Authors:  Ute Hegenbart; Dietger Niederwieser; Brenda M Sandmaier; Michael B Maris; Judith A Shizuru; Hildegard Greinix; Catherine Cordonnier; Bernard Rio; Alois Gratwohl; Thoralf Lange; Haifa Al-Ali; Barry Storer; David Maloney; Peter McSweeney; Thomas Chauncey; Ed Agura; Benedetto Bruno; Richard T Maziarz; Finn Petersen; Rainer Storb
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

5.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

6.  Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.

Authors:  Michael B Maris; Brenda M Sandmaier; Barry E Storer; David G Maloney; Judith A Shizuru; Edward Agura; Constanze Kliem; Michael Pulsipher; Richard T Maziarz; Peter A McSweeney; James Wade; Amelia A Langston; Thomas R Chauncey; Benedetto Bruno; Karl G Blume; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2006-04       Impact factor: 5.742

7.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

8.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Authors:  Naoyuki Uchida; Atsushi Wake; Shinsuke Takagi; Hisashi Yamamoto; Daisuke Kato; Yoshiko Matsuhashi; Tomoko Matsumura; Sachiko Seo; Naofumi Matsuno; Kazuhiro Masuoka; Eiji Kusumi; Koichiro Yuji; Shigesaburo Miyakoshi; Michio Matsuzaki; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

9.  Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

Authors:  Christopher N Bredeson; Mei-Jie Zhang; Manza-A Agovi; Andrea Bacigalupo; Nizar J Bahlis; Karen Ballen; Christopher Brown; M Ahsan Chaudhry; Mary M Horowitz; Seira Kurian; Diana Quinlan; Catherine E Muehlenbien; James A Russell; Lynn Savoie; J Douglas Rizzo; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

10.  Umbilical cord blood transplantation using non-myeloablative conditioning: the Mexican experience.

Authors:  Consuelo Mancías-Guerra; Guillermo J Ruiz-Delgado; Carlos Manzano; Maria Angeles Díaz-Hernandez; Luz C Tarín-Arzaga; Oscar González-Llano; David Gómez-Almaguer; Guillermo J Ruiz-Argüelles
Journal:  Hematology       Date:  2006-10       Impact factor: 2.269

View more
  9 in total

Review 1.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

2.  Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function.

Authors:  Jianqiang Li; Ian Nicoud; Joseph Blake; David Oliver; Emily Cox; Shelly Heimfeld; Filippo Milano; Suzan Imren; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-19       Impact factor: 5.742

3.  Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.

Authors:  Filippo Milano; Jonathan A Gutman; H Joachim Deeg; Eneida R Nemecek; Joachim Baumgart; Laurel Thur; Ann Dahlberg; Rachel B Salit; Corinne Summers; Frederick R Appelbaum; Colleen Delaney
Journal:  Blood Adv       Date:  2020-07-28

Review 4.  Thinking out of the box--new approaches to controlling GVHD.

Authors:  Frédéric Baron; Stéphanie Humblet-Baron; Grégory Ehx; Sophie Servais; Muriel Hannon; Ludovic Belle; Chantal Lechanteur; Alexandra Briquet; Olivier Giet; Etienne Baudoux; Evelyne Willems; Yves Beguin
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

5.  Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

Authors:  Judith A E Somers; Eric Braakman; Bronno van der Holt; Eefke J Petersen; Erik W A Marijt; Cynthia Huisman; Kees Sintnicolaas; Machteld Oudshoorn; Marlies E Groenendijk-Sijnke; Anneke Brand; Jan J Cornelissen
Journal:  Haematologica       Date:  2014-08-08       Impact factor: 9.941

6.  High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Authors:  Doris M Ponce; Patrick Hilden; Sean M Devlin; Molly Maloy; Marissa Lubin; Hugo Castro-Malaspina; Parastoo Dahi; Katharine Hsu; Ann A Jakubowski; Nancy A Kernan; Guenther Koehne; Richard J O'Reilly; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig Sauter; Andromachi Scaradavou; Roni Tamari; Marcel R M van den Brink; James W Young; Sergio Giralt; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-31       Impact factor: 5.742

Review 7.  Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Authors:  Mohamed L Sorror; Frederick R Appelbaum
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

8.  The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.

Authors:  Claudio Brunstein; Mei-Jie Zhang; Juliet Barker; Andrew St Martin; Asad Bashey; Marcos de Lima; Jason Dehn; Peiman Hematti; Miguel-Angel Perales; Vanderson Rocha; Mary Territo; Daniel Weisdorf; Mary Eapen
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

9.  Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.

Authors:  Claudio G Brunstein; Todd E DeFor; Ephraim J Fuchs; Chatchada Karanes; Joseph P McGuirk; Andrew R Rezvani; Mary Eapen; Paul V O'Donnell; Daniel J Weisdorf
Journal:  Transplant Cell Ther       Date:  2021-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.